TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06335576

Intervention type: OTHER
Intervention: This study is a single-arm and observational study with no intervention.
Description: This study is a single-arm and observational study with no intervention.
Study: NCT06020963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Intensity Shockwave Therapy (LiSWT)
Description: Low Intensity Shockwave Therapy (LiSWT) has been used for many years. Its mechanism is to use shock wave energy to promote angiogenesis to achieve the functions of tissue repair and cell regeneration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Intensity Shockwave Therapy (LiSWT)
Description: Low Intensity Shockwave Therapy (LiSWT) has been used for many years. Its mechanism is to use shock wave energy to promote angiogenesis to achieve the functions of tissue repair and cell regeneration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin is a selective alpha-1 blocker, its main function is to relax the smooth muscles of the base of the prostate, urethra, and bladder, and improve lower urinary tract symptoms.
Study: NCT05639777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Description: That will receive intranasal dexmedetomidine (1.5mcg/kg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: That will receive the same volume of 2 ml of intranasal normal saline
Study: NCT05573334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioNourish
Description: BioNourish is a 510k-cleared class II medical device that has been on the market for over two years. It is a vaginal moisturizing gel that is designed with pH, osmolality, and lactic acid levels that match those observed in healthy vaginas. It does not have an active ingredient, but only provides moisture in a formula that is matched for physicochemical characteristics to healthy vaginal fluid.
Study: NCT05263336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verdye Green
Description: intraoperative iv application of indocyanic green for visualisation of blood supply to the anastomosis after rectal cancer recection
Study: NCT05355623

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Repair
Description: Vaginal Repair will be done either by application of sterilized (gamma irradiated) amniotic membrane or by Classical repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Repair
Description: Vaginal Repair will be done either by application of sterilized (gamma irradiated) amniotic membrane or by Classical repair
Study: NCT04982445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABENUVA
Description: CABENUVA will be administered IM at infusion centers/ASAs
Study: NCT06078787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 150 MG
Description: Olaparib should be dosed 2 x 150 mg tablets (300 BID)
Study: NCT04686318

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers for acute pyelonephritis
Description: Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of CRP, PCT and suPAR. Laboratory staff will be blinded to participant diagnosis and outcome. CRP and PCT results will be available to the treating physician, but the suPAR result will not be available.~* Diagnostic test of CRP. CRP will be measured using an immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi Cobas© systems.~* Diagnostic test of PCT: Plasma PCT will be quantified by an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas© within two hours from collection according to standard procedure.~* Diagnostic test of suPAR: Plasma suPAR will be quantified by using the commercial available suPARnostic© Tubilatex assay reagents (ViroGates, Denmark) on Cobas© as previously validated (35). Separated plasma is kept refrigerated and analysed for suPAR within 48 hours after collection.
Study: NCT04869904

Intervention type: PROCEDURE
Intervention: dental and plaque sampling
Description: sampling of dental plaque and saliva during the treatment

Intervention type: PROCEDURE
Intervention: dental and plaque sampling
Description: sampling of dental plaque and saliva during the treatment
Study: NCT05511831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen Fumarate
Description: Ketotifen treatment for 3 months, 1 mg each time, 1-2 times a day according to the patient's tolerance

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: standard treatment
Description: Standard treatment methods will be determined according to the Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2019) \[19\], including primary PCI, dual antiplatelet, anticoagulation, ACEI/ARB/ARNI, β-receptor blockade drugs, statins, etc.
Study: NCT05657782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanChol
Description: PanChol is a new second generation live-attenuated oral cholera vaccine (OCV) that circumvents limitations of previous live-attenuated OCVs. In contrast to other live OCVs, PanChol is derived from a current circulating pandemic V. cholerae strain, thus eliminating the risk of vaccine-derived genes from extinct V. cholerae strains (such as CVD 103-HgR) recombining with circulating V. cholerae strains.
Study: NCT05978739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib High dose
Description: Orelabrutinib will be administered as 3 tablets once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib Low dose
Description: Orelabrutinib will be administered as 1 tablet once per day
Study: NCT06326502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETN101
Description: Oral administration
Study: NCT05636566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: inhalational anaesthesia for maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol infusion for maintance
Description: propofol infusion after induction for maintenance of anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia
Study: NCT05859321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality Exercises
Description: Virtual reality exercises along with transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physiotherapy
Description: transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises
Study: NCT04731402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure, laughter yoga and mindfulness stress reduction program
Description: Initiatives will be applied to the experimental group. only measurement tools will be applied to the control group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure, laughter yoga and mindfulness stress reduction program
Description: Initiatives will be applied to the experimental group. only measurement tools will be applied to the control group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure, laughter yoga and mindfulness stress reduction program
Description: Initiatives will be applied to the experimental group. only measurement tools will be applied to the control group
Study: NCT06551220

Intervention type: DRUG
Intervention: Trastuzumab Deruxtecan
Description: The patients received Trastuzumab Deruxtecan at a dose of 5.4 mg/kg every 3 weeks until disease progression or unacceptable adverse effects occurred.
Study: NCT06078566

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AUR-201
Description: Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
Study: NCT05544253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mitomycin C-based hyperthermic intraperitoneal chemotherapy
Description: The patients with srHCC or PM of HCC were randomly allocated to either the HIPEC group or the control group. All of them have received open liver resection and perfusion tubes had been set in the operation. For patients with PM of HCC served operation, we are subject to reach CC score at 0-1 to creating sufficient conditions for HIPEC. Finally, place the HIPEC tubes. Implementation of HIPEC was administered 3times on the 1st, 3rd, 5th days within one week after operation. We used intraperitoneal hyperthermic perfusion device (BR-TRG-IITM, Bao Rui medical corporation, Guangdong, China) to achieve HIPEC. The abdominal temperature was maintained at 43°C (109°F) by circulating heated saline. The perfusion volume was 3000ml of normal saline, and the chemotherapeutic agent of mitomycin C was 10mg for a 1-hour perfusion period.
Study: NCT04868292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR206
Description: Three 100 mg SPR206 intravenous doses administered every 8 hours
Study: NCT06504836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait training with biofeedback
Description: Gait training include treadmill and overground walking. The biofeedback device system will provide real-time feedback on hip extension angles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait training without biofeedback
Description: Gait training include treadmill and overground walking.
Study: NCT05657782

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PanChol
Description: PanChol is a new second generation live-attenuated oral cholera vaccine (OCV) that circumvents limitations of previous live-attenuated OCVs. In contrast to other live OCVs, PanChol is derived from a current circulating pandemic V. cholerae strain, thus eliminating the risk of vaccine-derived genes from extinct V. cholerae strains (such as CVD 103-HgR) recombining with circulating V. cholerae strains.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PanChol
Description: PanChol is a new second generation live-attenuated oral cholera vaccine (OCV) that circumvents limitations of previous live-attenuated OCVs. In contrast to other live OCVs, PanChol is derived from a current circulating pandemic V. cholerae strain, thus eliminating the risk of vaccine-derived genes from extinct V. cholerae strains (such as CVD 103-HgR) recombining with circulating V. cholerae strains.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanChol
Description: PanChol is a new second generation live-attenuated oral cholera vaccine (OCV) that circumvents limitations of previous live-attenuated OCVs. In contrast to other live OCVs, PanChol is derived from a current circulating pandemic V. cholerae strain, thus eliminating the risk of vaccine-derived genes from extinct V. cholerae strains (such as CVD 103-HgR) recombining with circulating V. cholerae strains.
Study: NCT05319626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compression socks
Description: The compression socks have a clinical pressure of 23-30 mm Hg. The socks are dressed to the participants based on the manufacturer's sizing guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compression socks
Description: The compression socks have a clinical pressure of 23-30 mm Hg. The socks are dressed to the participants based on the manufacturer's sizing guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: textured insoles
Description: The textured insoles have small, pyramidal peaks with centre-to-centre distances of approximately 2.5 mm (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: textured insoles
Description: The textured insoles have small, pyramidal peaks with centre-to-centre distances of approximately 2.5 mm (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: smooth socks
Description: The smooth socks are a commercial stocking that does not have a compression feature, but has a similar thickness and color to the compression stocking. They have standard size.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smooth socks
Description: The smooth socks are a commercial stocking that does not have a compression feature, but has a similar thickness and color to the compression stocking. They have standard size.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: smooth insoles
Description: The smooth insoles have a completely flat surface (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smooth insoles
Description: The smooth insoles have a completely flat surface (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
Study: NCT04865250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg abs day 1 q22 (iv)
Description: Immune checkpoint blockade antibody ATEZOLIZUMAB directed against PD-L1 (Programmed death-ligand 1); Carboplatin; Nab-Paclitaxel (iv)
Study: NCT05811767

Intervention type: OTHER
Intervention: Health Examination
Description: The study is a cross-sectional study and therefore there is no intervention. The study consist only of tests, questionnaires and a blood test. See the elements under outcomes measures.
Study: NCT05543460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MARPE with Corticopunctures
Description: Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency aided with corticopunctures made along the mid-palatal suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MARPE
Description: Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency
Study: NCT05092295

Intervention type: DEVICE
Intervention: Head and Intraocular Trauma Tool
Description: HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.

Intervention type: DEVICE
Intervention: Head and Intraocular Trauma Tool
Description: HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.

Intervention type: DIAGNOSTIC_TEST
Intervention: SCAT-5
Description: Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.

Intervention type: DIAGNOSTIC_TEST
Intervention: SCAT-5
Description: Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
Study: NCT05738499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Character strengths-based structured treatment and education programme (CSSTEP)
Description: This CSSTEP intervention included both psychological and educational contents, and the intervention type was psycho-educational intervention. The implementation process lasted for three weeks. CSSTEP mainly includes two main components. The first part is character strengths-based intervention. The second part is educational intervention, which is structured treatment and education programme for stroke patients. The two components were combined and optimized on the basis of theoritical and empirical evidences, and then this kind of complex intervention suitable for Chinese clinical stroke patients was obtained.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Structured treatment and education programme (STEP)
Description: The STEP programme is aimed at the treatment needs of stroke patients, considering the education level and cultural background of patients, screening important health education content, and planning and grading of patients' education. The intervention consisted of three educational sessions, focusing on patients' daily life, post-stroke rehabilitation and secondary prevention.
Study: NCT05222737

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: medency diode laser
Description: intra pocket application of diode laser

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spirazole forte
Description: adminstration of spirazole forte with a dose 17 mg per kg
Study: NCT05176145

Intervention type: DEVICE
Group type: OTHER
Intervention: VisioCyt®
Description: * Cytological and endoscopic examination is planned as part of the usual management of patients under surveillance of Non-muscle invasive bladder cancer (NMIBC), according to the CCAFU guidelines.~* Urine collection for conventional cytology and VisioCyt® test
Study: NCT04790604

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community Health Navigator Program
Description: Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Navigator Program
Description: Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
Study: NCT05611840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Description: one-stage robotic common bile duct exploration and cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endo-laparoscopic surgery
Description: Two-stage therapeutic ERCP plus interval laparoscopic cholecystectomy
Study: NCT04831515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A
Description: daily disposable soft contact lens - test lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens A
Description: daily disposable soft contact lens - test lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B
Description: daily disposable soft contact lens - control lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens B
Description: daily disposable soft contact lens - control lens
Study: NCT05177601

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of mood disorders.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of mood disorders.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: Daily oral D-cycloserine 100mg during TMS treatments (20 days).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: D-cycloserine
Description: Daily oral D-cycloserine 100mg during TMS treatments (20 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Daily oral placebo during the TMS treatments (20 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Daily oral placebo during the TMS treatments (20 days).
Study: NCT05559281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botulinum
Description: injection of Botulinum Toxin injection in lip muscles following cleft lip repair surgically.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fisher technique
Description: The cleft lip will be treated surgically using the Fisher technique only.
Study: NCT06112899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Hamstring Exercise
Description: The NHE, also referred to as the nordic curl, is designed to improve eccentric strength of the hamstring muscles. Individuals start in a kneeling position, with the torso from the knees upward held rigid and straight. The training partner ensures that the individual's feet are in contact with the ground throughout the exercise by applying pressure to the player's heels/lower legs. The individual then lowers his upper body to the ground, as slowly as possible to maximize loading in the eccentric phase. Hands and arms are used to break his forward fall and to push him back up after the chest has touched the ground, to minimize loading in the concentric phase.The exercise protocol is planned as 5 sets of 8 repetitions and 2 minutes of rest between each set.